ESMO 2025 preview – Astra and Daiichi keep abreast of Gilead
Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.
ESMO 2025 preview – Merck hopes for Daiichi redemption
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
ESMO 2025 preview – Enhertu's early breast hat-trick
The ESMO presidential session will feature data from Destiny-Breast05 and 11.
ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
Neither Arvinas nor Pfizer now wants vepdegestrant
So who else could be interested in the oestrogen degrader?
Astra and J&J tussle over first-line lung
The companies clash over survival curve similarities – and differences.
World Lung 2025 – crossing curves in lung cancer
Tolerability could decide first-line therapy in EGFRm disease.
The month ahead: September’s upcoming events
It’s a new term for biotech and its investors.
FDA doubles down on overall survival
New draft guidance could see the agency getting ever stricter.
